Compare Cytokinetics Inc (CYTK) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Toyota Motor Corp — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Toyota Motor Corp trades at $184.98 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 25.2× Cytokinetics Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Toyota Motor Corp for 116 Days on average.
| CYTK | TM | |
|---|---|---|
Market Cap | $8.62B | $217.38B |
Volume | 2,594,626 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $248.29 |
52-Week Low | $54.76 | $166.50 |
Typical Hold Time | 19 Days | 116 Days |
Enterprise Value | $8.72B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Toyota Motor trades at $184.84, up 1.06% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while delivering consistent earnings beats. Recent U.S. sales growth and electrification progress contrast with China market challenges and production disruptions from Thailand floods.
Toyota presents a value opportunity with solid profitability and market share gains, though technical weakness and regional sales pressures warrant caution. The company's electrification investments and strong U.S. position support long-term growth, while currency risks and competitive pressures remain key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
